These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 22013558)

  • 21. Effects of Cerebrolysin on amyloid-beta deposition in a transgenic model of Alzheimer's disease.
    Rockenstein E; Mallory M; Mante M; Alford M; Windisch M; Moessler H; Masliah E
    J Neural Transm Suppl; 2002; (62):327-36. PubMed ID: 12456076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmacological approaches to the therapy of Alzheimer's disease].
    Gavrilova SI
    Vestn Ross Akad Med Nauk; 2006; (9-10):30-4. PubMed ID: 17111921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurotrophic activities and therapeutic experience with a brain derived peptide preparation.
    Windisch M; Gschanes A; Hutter-Paier B
    J Neural Transm Suppl; 1998; 53():289-98. PubMed ID: 9700665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders.
    Masliah E; Díez-Tejedor E
    Drugs Today (Barc); 2012 Apr; 48 Suppl A():3-24. PubMed ID: 22514792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease.
    Alvarez XA; Cacabelos R; Laredo M; Couceiro V; Sampedro C; Varela M; Corzo L; Fernandez-Novoa L; Vargas M; Aleixandre M; Linares C; Granizo E; Muresanu D; Moessler H
    Eur J Neurol; 2006 Jan; 13(1):43-54. PubMed ID: 16420392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spotlight on cerebrolysin in dementia.
    Plosker GL; Gauthier S
    CNS Drugs; 2010 Mar; 24(3):263-6. PubMed ID: 20155999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic results with Cerebrolysin in the treatment of dementia.
    Rainer M; Brunnbauer M; Dunky A; Ender F; Goldsteiner H; Holl O; Kotlan P; Paulitsch G; Reiner C; Stössl J; Zachhuber C; Mössler H
    Wien Med Wochenschr; 1997; 147(18):426-31. PubMed ID: 9408984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cerebrolysin enhances cognitive recovery of mild traumatic brain injury patients: double-blind, placebo-controlled, randomized study.
    Chen CC; Wei ST; Tsaia SC; Chen XX; Cho DY
    Br J Neurosurg; 2013 Dec; 27(6):803-7. PubMed ID: 23656173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cerebrolysin ameliorates performance deficits, and neuronal damage in apolipoprotein E-deficient mice.
    Masliah E; Armasolo F; Veinbergs I; Mallory M; Samuel W
    Pharmacol Biochem Behav; 1999 Feb; 62(2):239-45. PubMed ID: 9972690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved global function and activities of daily living in patients with AD: a placebo-controlled clinical study with the neurotrophic agent Cerebrolysin.
    Muresanu DF; Rainer M; Moessler H
    J Neural Transm Suppl; 2002; (62):277-85. PubMed ID: 12456070
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Cognitive impairment and tactics of using the drug Cerebrolysin. Resolution of the International Council of Experts (May 12, 2023)].
    Levin OS; Voznyuk IA; Illarioshkin SN; Tkacheva ON; Bogolepova AN; Vasenina EE; Gavrilova SI; Dokukina TV; Emelin AY; Lobzin VY; Mkhitaryan EA; Khatkova SE; Yakushin MA; Yanishevskiy SN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(9):121-130. PubMed ID: 37796079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Current conceptions of neurocytoprotective therapy].
    Gomazkov OA; Afanas'ev VV; Rumiantseva SA; Stupin VA; Silina EV; Sokhova OA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(12 Pt 2):58-63. PubMed ID: 22792751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The influence of cerebrolysin on the efficiency of subsequent therapy with amiridine++ in Alzheimer's disease patients (neuropsychological investigation)].
    Roshchina IF; Kolykhalov IV; Selezneva ND; Zharikov GA; Gerasimov NP; Gavrilova SI
    Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(12):43-6. PubMed ID: 10629930
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension study.
    Muresanu DF; Alvarez XA; Moessler H; Novak PH; Stan A; Buzoianu A; Bajenaru O; Popescu BO
    J Neurol Sci; 2010 Dec; 299(1-2):179-83. PubMed ID: 20923712
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Approach towards an integrative drug treatment of Alzheimer's disease.
    Windisch M
    J Neural Transm Suppl; 2000; 59():301-13. PubMed ID: 10961442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Neuroplasticity: main mechanisms and their clinical significance].
    Damulin IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(4):4-8. PubMed ID: 19491802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use.
    Gavrilova SI; Alvarez A
    Med Res Rev; 2021 Sep; 41(5):2775-2803. PubMed ID: 32808294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer's disease with the neurotrophic compound cerebrolysin.
    Rockenstein E; Adame A; Mante M; Larrea G; Crews L; Windisch M; Moessler H; Masliah E
    J Neural Transm (Vienna); 2005 Feb; 112(2):269-82. PubMed ID: 15657642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alzheimer's disease: cerebrolysin and nanotechnology as a therapeutic strategy.
    Sharma HS; Muresanu DF; Sharma A
    Neurodegener Dis Manag; 2016 Dec; 6(6):453-456. PubMed ID: 27827552
    [No Abstract]   [Full Text] [Related]  

  • 40. Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT).
    Rüther E; Ritter R; Apecechea M; Freytag S; Windisch M
    Pharmacopsychiatry; 1994 Jan; 27(1):32-40. PubMed ID: 8159781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.